Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Alvotech Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.67 billion
Book Value:
Revenue TTM:
$85.02 million
Operating Margin TTM:
Gross Profit TTM:
$20.92 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Alvotech had its IPO on 2022-06-16 under the ticker symbol ALVO.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Alvotech has a staff strength of 784 employees.

Stock update

Shares of Alvotech opened at $13.47 at the start of the last trading session i.e. 2023-03-28.

The stocks traded within a range of $13.13 - $13.74, and closed at $13.2.

This is a -2.29% slip from the previous day's closing price.

A total volume of 120,824 shares were traded at the close of the day’s session.

In the last one week, shares of Alvotech have slipped by -1.71%.

Alvotech's Key Ratios

Alvotech has a market cap of $3.67 billion, indicating a price to book ratio of 0 and a price to sales ratio of 20.6922.

In the last 12-months Alvotech’s revenue was $85.02 million with a gross profit of $20.92 million and an EBITDA of $-333569984. The EBITDA ratio measures Alvotech's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alvotech’s operating margin was -404.26% while its return on assets stood at -30.12% with a return of equity of 0%.

In Q4, Alvotech’s quarterly earnings growth was a positive 0% while revenue growth was a negative 30.2%.

Alvotech’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $0.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alvotech’s profitability.

Alvotech stock is trading at a EV to sales ratio of 28.6123 and a EV to EBITDA ratio of 29.6456. Its price to sales ratio in the trailing 12-months stood at 20.6922.

Alvotech stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$828.44 million
Total Liabilities
$167.29 million
Operating Cash Flow
Capital Expenditure
$10.47 million
Dividend Payout Ratio

Alvotech ended 2023 with $828.44 million in total assets and $0 in total liabilities. Its intangible assets were valued at $828.44 million while shareholder equity stood at $-564416000.00.

Alvotech ended 2023 with $0 in deferred long-term liabilities, $167.29 million in other current liabilities, in common stock, $-1654114000.00 in retained earnings and $11.64 million in goodwill. Its cash balance stood at $66.43 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $744.65 million.

Alvotech’s total current assets stands at $230.74 million while long-term investments were $48.57 million and short-term investments were $0. Its net receivables were $32.97 million compared to accounts payable of $49.19 million and inventory worth $71.47 million.

In 2023, Alvotech's operating cash flow was $0 while its capital expenditure stood at $10.47 million.

Comparatively, Alvotech paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Alvotech stock is currently trading at $13.2 per share. It touched a 52-week high of $14.6 and a 52-week low of $14.6. Analysts tracking the stock have a 12-month average target price of $12.8.

Its 50-day moving average was $13.05 and 200-day moving average was $0 The short ratio stood at 4.2 indicating a short percent outstanding of 0%.

Around 7364.3% of the company’s stock are held by insiders while 758.6% are held by institutions.

Frequently Asked Questions About Alvotech

The stock symbol (also called stock or share ticker) of Alvotech is ALVO

The IPO of Alvotech took place on 2022-06-16

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price

Most Active

Last Price
Bird Global (BRDS)

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.


Saemundargata 15-19, Reykjavik, Iceland, 102